PT-141
Also known as · Bremelanotide
Overview
A cyclic heptapeptide melanocortin-receptor agonist studied in CNS-mediated sexual response research. Acts on hypothalamic melanocortin circuits rather than vascular pathways.
Research profile · for clinicians
Based on research: studied as a centrally acting modulator of sexual response, distinct from vascular ED mechanisms. Acts on hypothalamic melanocortin circuits and has clinical trial data (RECONNECT) in premenopausal hypoactive sexual desire disorder.
Mechanism of action
Selective agonism of MC4R within hypothalamic nuclei modulates dopaminergic signaling associated with arousal pathways, independent of phosphodiesterase mechanisms.
Research record
- [01]RECONNECT trials in pre-menopausal HSDD cohorts.
Selected references
Bremelanotide for hypoactive sexual desire disorder
Obstet. Gynecol., 2019